LENZ Therapeutics has unveiled its national “Make it VIZZable” consumer campaign for VIZZ™ (aceclidine ophthalmic solution) 1.44%, partnering with award-winning actor and producer Sarah Jessica Parker. The campaign showcases Parker’s personal experience overcoming age-related blurry near vision—affecting an estimated 128 million Americans over 45—and highlights VIZZ’s once-daily eye drops that restore near vision for up to 10 hours. Advertisements feature Parker navigating New York City streets, reading text messages and price tags without reading glasses, emphasizing convenience and freedom in daily life. VIZZ is available by prescription through eye care professionals, and the campaign drives consumers to VIZZ.com to find a local provider offering free samples.

In the pivotal CLARITY Phase 3 clinical trial, VIZZ demonstrated robust efficacy: 93% of participants achieved 20/40 or better near vision within 30 minutes of instillation, with effects lasting up to 10 hours. The mechanism—a predominantly pupil-selective miotic effect causing a sub-2mm pupil “pinhole” to extend depth of focus—provided significant improvements without inducing myopic shift or heavy ciliary muscle stimulation. The profile includes 20% incidence of instillation-site irritation, 16% reporting dim vision and 13% headaches, with the majority of adverse reactions mild and transient. These data support VIZZ’s potential to displace over-the-counter reading glasses and multifocal contact lenses for presbyopia management.

Seven research firms currently cover LENZ Therapeutics, assigning a consensus “Moderate Buy” recommendation and an average 12-month target price of $56.40. Recent upgrades include Raymond James raising its target from $40.00 to $50.00 and Piper Sandler boosting its overweight target to $67.00. LENZ reported $12.5 million in revenue for the quarter ended September 30, 2025—driven primarily by initial VIZZ prescriptions—exceeding analysts’ forecast of $4.64 million. The company recorded a loss of $0.59 per share versus consensus of $0.67, reflecting scaled commercial investment. Institutional ownership stands at 54.3%, underscoring growing institutional conviction in LENZ’s commercialization trajectory.